Leqvio Clinical Trial Adverse Events by Incidence Rate
Injection-site reactions were most common (8.2% vs 1.8% placebo) across ORION-9/10/11. No significant liver, kidney, or muscle toxicity signals emerged.
V2 Inclisiran: Side Effects
5 source-based articles maintained by the HealthRX.com Editorial Team.
5articles
3topic areas covered
Jul 10, 2025latest review
V2 Inclisiran: Side Effects library
Showing 5 of 5 clinical reviews.
Leqvio Side Effects: How Common and How Severe Are They?
Injection-site reactions affect about 8.2% of Leqvio users and are usually mild. No withdrawal syndrome exists, but LDL-C rebounds within 6-12 months of stopping.
Leqvio Side Effects: How Common and How Severe?
Most Leqvio side effects are mild injection-site reactions (8.2% vs 1.8% placebo); permanent effects remain unconfirmed in trial data. See what to monitor.
Leqvio Side Effects: Rare but Serious Adverse Events Explained
A guide to the rare but serious adverse events linked to Leqvio (inclisiran), covering trial data, FDA labeling, post-market reports, and how to monitor patients on twice-yearly PCSK9i injections.
Long-Term Side Effects of Leqvio: What the Data Shows
Leqvio's long-term side effects are mostly mild injection-site reactions (8.2%); serious events match placebo, except in severe renal or hepatic impairment.